1.	Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 63325-001, NCT00409188
2.	Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR063325_009, NCT00960115
3.	Phase II Study of BLP25 Liposome Vaccine and Bevacizumab After Definitive Chemoradiotherapy in Patients With Newly Diagnosed, Unresectable Stage IIIA or IIIB Nonsquamous Cell Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E6508, E6508, NCT00828009
4.	Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials Phase: No phase specified Type: Natural history/Epidemiology Status: Enrolling by invitation Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMR 63325-011, NCT01423760